PXRB (PixarBio) Equity-to-Asset : 0.99 (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PixarBio's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $0.36 Mil. PixarBio's Total Assets for the quarter that ended in Sep. 2016 was $0.36 Mil. Therefore, PixarBio's Equity to Asset Ratio for the quarter that ended in Sep. 2016 was 0.99.

The historical rank and industry rank for PixarBio's Equity-to-Asset or its related term are showing as below:

PXRB's Equity-to-Asset is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

PixarBio Equity-to-Asset Historical Data

The historical data trend for PixarBio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Equity-to-Asset Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Equity-to-Asset

0.93

0.75

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Equity-to-Asset	Get a 7-Day Free Trial					0.75	0.75	0.64	0.51	0.99

Competitive Comparison of PixarBio's Equity-to-Asset

For the Biotechnology subindustry, PixarBio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PixarBio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PixarBio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PixarBio's Equity-to-Asset falls into.

PixarBio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PixarBio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Equity to Asset (A: Dec. 2015 )	=	Total Stockholders Equity	/	Total Assets
	=	0.278	/	0.369
	=	0.75

PixarBio's Equity to Asset Ratio for the quarter that ended in Sep. 2016 is calculated as

Equity to Asset (Q: Sep. 2016 )	=	Total Stockholders Equity	/	Total Assets
	=	0.357	/	0.362
	=	0.99

PixarBio (GREY:PXRB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

PixarBio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PixarBio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.